Cor Vasa 2022, 64(Suppl. 4):48-57

The year in cardiovascular medicine 2021: valvular heart disease

Helmut Baumgartner1*, Bernard Iung2, David Messika-Zeitoun3, Catherine M. Otto4
1 Department of Cardiology III-Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, Muenster 48149, Germany
2 Department of Cardiology, Bichat Hospital, APHP, Université de Paris, Paris, France
3 Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada
4 Division of Cardiology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA

Received Date: 15 September 2021; Revision received Date: 15 October 2021; Accepted Date: 23 December 2021
Reproduced from: Baumgartner H, Iung B, Messika-Zeitoun D, Otto CM. The year in cardiovascular medicine 2021: valvular heart disease. Eur Heart J 2022;43:633–640, https://doi.org/10.1093/eurheartj/ehab885, by permission of Oxford University Press on behalf of the European Society of Cardiology.

Keywords: Valvular heart disease, Review, Aortic stenosis, Mitral regurgitation, Tricuspid regurgitation, Infective endocarditis, Prosthetic heart valve

Received: December 19, 2022; Accepted: December 19, 2022; Published: December 30, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Baumgartner H, Iung B, Messika-Zeitoun D, Otto CM. The year in cardiovascular medicine 2021: valvular heart disease. Cor Vasa. 2022;64(Suppl. 4):48-57.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2021:ehab395. Go to original source... Go to PubMed...
    2. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020;143:e72-e227. Go to original source... Go to PubMed...
    3. Pawade TA, Doris MK, Bing R, White AC, Forsyth L, Evans E, et al. Effect of denosumab or alendronic acid on the progression of aortic stenosis: a double-blind randomized controlled trial. Circulation 2021;143:2418-2427. Go to original source... Go to PubMed...
    4. Lee S, Lee S-A, Choi B, Kim Y-J, Oh SJ, Choi H-M, et al. Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis. Heart 2020;106:1824-1831. Go to original source... Go to PubMed...
    5. Pérez de Isla L, Watts GF, Alonso R, Díaz-Díaz JL, Muñiz-Grijalvo O, Zambón D, et al. Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. Eur Heart J 2021;42:2201-2211. Go to original source... Go to PubMed...
    6. Mosleh W, Amer MR, Ding Y, Megaly M, Mather JF, McMahon S, et al. Benefit of transcatheter aortic valve replacement in patients with paradoxical low-flow low-gradient versus high-gradient aortic stenosis and preserved left ventricular function. Circ Cardiovasc Interv 2021;14:e010042. Go to original source... Go to PubMed...
    7. Ueyama H, Kuno T, Harrington M, Takagi H, Krishnamoorthy P, Sharma SK, et al. Impact of surgical and transcatheter aortic valve replacement in low-gradient aortic stenosis: a meta-analysis. JACC Cardiovasc Interv 2021;14:1481-1492. Go to original source... Go to PubMed...
    8. Freitas-Ferraz AB, Nombela-Franco L, Urena M, Maes F, Veiga G, Ribeiro H, et al. Transcatheter aortic valve replacement in patients with paradoxical low-flow, low-gradient aortic stenosis: incidence and predictors of treatment futility. Int J Cardiol 2020;316:57-63. Go to original source... Go to PubMed...
    9. Bienjonetti-Boudreau D, Fleury M-A, Voisine M, Paquin A, Chouinard I, Tailleur M, et al. Impact of sex on the management and outcome of aortic stenosis patients. Eur Heart J 2021;42:2683-2691. Go to original source... Go to PubMed...
    10. Michelena HI, Della Corte A, Evangelista A, Maleszewski JJ, Edwards WD, Roman MJ, et al. International consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and research purposes. Eur J Cardiothorac Surg 2021;60:448-476. Go to original source... Go to PubMed...
    11. Banovic M, Putnik S, Penicka M, Doros G, Deja MA, Kockova R, et al. Aortic valve ReplAcemenT versus conservative treatment in asymptomatic SeveRe aortic stenosis: the AVATAR trial. Circulation; https://doi.org/10.1161/CIRCULATIONAHA.121.057639. Published online ahead of print 13 November 2021. Go to original source... Go to PubMed...
    12. Jean G, Van Mieghem NM, Gegenava T, van Gils L, Bernard J, Geleijnse ML, et al. Moderate aortic stenosis in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2021;77:2796-2803. Go to original source... Go to PubMed...
    13. Albassam O, Henning KA, Qiu F, Cram P, Sheth TN, Ko DT, et al. Increasing wait-time mortality for severe aortic stenosis: a population-level study of the transition in practice from surgical aortic valve replacement to transcatheter aortic valve replacement. Circ Cardiovasc Interv 2020;13:e009297. Go to original source... Go to PubMed...
    14. Zhang X-L, Zhang X-W, Lan R-F, Chen Z, Wang L, Xu W, et al. Long-term and temporal outcomes of transcatheter versus surgical aortic-valve replacement in severe aortic stenosis: a meta-analysis. Ann Surg 2021;273:459-466. Go to original source... Go to PubMed...
    15. Leon MB, Mack MJ, Hahn RT, Thourani VH, Makkar R, Kodali SK, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol 2021;77:1149-1161. Go to original source... Go to PubMed...
    16. Jørgensen TH, Thyregod HGH, Ihlemann N, Nissen H, Petursson P, Kjeldsen BJ, et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart J 2021;42:2912-2919. Go to original source... Go to PubMed...
    17. Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG, et al. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med 2020;382:799-809. Go to original source... Go to PubMed...
    18. Pibarot P, Ternacle J, Jaber WA, Salaun E, Dahou A, Asch FM, et al. Structural deterioration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2 trial. J Am Coll Cardiol 2020;76:1830-1843. Go to original source... Go to PubMed...
    19. Barbanti M, Costa G, Picci A, Criscione E, Reddavid C, Valvo R, et al. Coronary cannulation after transcatheter aortic valve replacement: the RE-ACCESS study. JACC Cardiovasc Interv 2020;13:2542-2555. Go to original source... Go to PubMed...
    20. Kim WK, Pellegrini C, Ludwig S, Möllmann H, Leuschner F, Makkar R, et al. Feasibility of coronary access in patients with acute coronary syndrome and previous TAVR. JACC Cardiovasc Interv 2021;14:1578-1590. Go to original source... Go to PubMed...
    21. Buzzatti N, Montorfano M, Romano V, De Backer O, Sondergaard L, Rosseel L, et al. A computed tomography study of coronary access and coronary obstruction after redo transcatheter aortic valve implantation. EuroIntervention 2020;16:e1005-e1013. Go to original source... Go to PubMed...
    22. Faroux L, Lhermusier T, Vincent F, Nombela-Franco L, Tchetche D, Barbanti M, et al. ST-segment elevation myocardial infarction following transcatheter aortic valve replacement. J Am Coll Cardiol 2021;77:2187-2199. Go to original source... Go to PubMed...
    23. Woldendorp K, Indja B, Bannon PG, Fanning JP, Plunkett BT, Grieve SM. Silent brain infarcts and early cognitive outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis. Eur Heart J 2021;42:1004-1015. Go to original source... Go to PubMed...
    24. Butala NM, Makkar R, Secemsky EA, Gallup D, Marquis-Gravel G, Kosinski AS, et al. Cerebral embolic protection and outcomes of transcatheter aortic valve replacement: results from the transcatheter valve therapy registry. Circulation 2021;143:2229-2240. Go to original source... Go to PubMed...
    25. Lansky AJ, Makkar R, Nazif T, Messé S, Forrest J, Sharma R, et al. A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. Eur Heart J 2021;42:2670-2679. Go to original source... Go to PubMed...
    26. Stachon P, Kaier K, Heidt T, Wolf D, Duerschmied D, Staudacher D, et al. The use and outcomes of cerebral protection devices for patients undergoing transfemoral transcatheter aortic valve replacement in clinical practice. JACC Cardiovasc Interv 2021;14:161-168. Go to original source... Go to PubMed...
    27. Ten Berg J, Sibbing D, Rocca B, Van Belle E, Chevalier B, Collet JP, et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Eur Heart J 2021;42:2265-2269. Go to original source... Go to PubMed...
    28. Didier R, Lhermusier T, Auffret V, Eltchaninoff H, Le Breton H, Cayla G, et al. TAVR patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist? JACC Cardiovasc Interv 2021;14:1704-1713. Go to original source... Go to PubMed...
    29. Kawashima H, Watanabe Y, Hioki H, Kozuma K, Kataoka A, Nakashima M, et al. Direct oral anticoagulants versus vitamin k antagonists in patients with atrial fibrillation after TAVR. JACC Cardiovasc Interv 2020;13:2587-2597. Go to original source... Go to PubMed...
    30. Van Mieghem NM, Unverdorben M, Hengstenberg C, Möllmann H, Mehran R, López-Otero D, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med 2021;385:2150-2160. Go to original source... Go to PubMed...
    31. Kobari Y, Inohara T, Saito T, Yoshijima N, Tanaka M, Tsuruta H, et al. Aspirin versus clopidogrel as single antithrombotic therapy after transcatheter aortic valve replacement: insight from the OCEAN-TAVI registry. Circ Cardiovasc Interv 2021;14:e010097. Go to original source... Go to PubMed...
    32. Rogers T, Shults C, Torguson R, Shea C, Parikh P, Bilfinger T, et al. Randomized trial of aspirin versus warfarin after transcatheter aortic valve replacement in low-risk patients. Circ Cardiovasc Interv 2021;14:e009983. Go to original source... Go to PubMed...
    33. Witberg G, Codner P, Landes U, Schwartzenberg S, Barbanti M, Valvo R, et al. Effect of transcatheter aortic valve replacement on concomitant mitral regurgitation and its impact on mortality. JACC Cardiovasc Interv 2021;14:1181-1192. Go to original source... Go to PubMed...
    34. Witberg G, Codner P, Landes U, Barbanti M, Valvo R, De Backer O, et al. Transcatheter treatment of residual significant mitral regurgitation following TAVR: a multicenter registry. JACC Cardiovasc Interv 2020;13:2782-2791. Go to original source... Go to PubMed...
    35. Kato N, Padang R, Scott CG, Guerrero M, Pislaru SV, Pellikka PA. The natural history of severe calcific mitral stenosis. J Am Coll Cardiol 2020;75:3048-3057. Go to original source... Go to PubMed...
    36. Bertrand PB, Churchill TW, Yucel E, Namasivayam M, Bernard S, Nagata Y, et al. Prognostic importance of the transmitral pressure gradient in mitral annular calcification with associated mitral valve dysfunction. Eur Heart J 2020;41:4321-4328. Go to original source... Go to PubMed...
    37. Kato N, Pislaru SV, Padang R, Pislaru C, Scott CG, Nkomo VT, et al. A novel assessment using projected transmitral gradient improves diagnostic yield of Doppler hemodynamics in rheumatic and calcific mitral stenosis. JACC Cardiovasc Imaging 2021;14:559-570. Go to original source... Go to PubMed...
    38. Urena M, Vahanian A, Brochet E, Ducrocq G, Iung B, Himbert D. Current indications for transcatheter mitral valve replacement using transcatheter aortic valves: valve-in-valve, valve-in-ring, and valve-in-mitral annulus calcification. Circulation 2021;143:178-196. Go to original source... Go to PubMed...
    39. Guerrero M, Wang DD, Eleid MF, Pursnani A, Salinger M, Russell HM, et al. Prospective study of TMVR using balloon-expandable aortic transcatheter valves in MAC: MITRAL trial 1-year outcomes. JACC Cardiovasc Interv 2021;14:830-845. Go to original source... Go to PubMed...
    40. Constant Dit Beaufils A-L, Huttin O, Jobbe-Duval A, Senage T, Filippetti L, Piriou N, et al. Replacement myocardial fibrosis in patients with mitral valve prolapse: relation to mitral regurgitation, ventricular remodeling, and arrhythmia. Circulation 2021;143:1763-1774. Go to original source... Go to PubMed...
    41. Essayagh B, Sabbag A, Antoine C, Benfari G, Yang L-T, Maalouf J, et al. Presentation and outcome of arrhythmic mitral valve prolapse. J Am Coll Cardiol 2020;76:637-649. Go to original source... Go to PubMed...
    42. van Wijngaarden AL, de Riva M, Hiemstra YL, van der Bijl P, Fortuni F, Bax JJ, et al. Parameters associated with ventricular arrhythmias in mitral valve prolapse with significant regurgitation. Heart 2021;107:411-418. Go to original source... Go to PubMed...
    43. Essayagh B, Sabbag A, Antoine C, Benfari G, Batista R, Yang LT, et al. The mitral annular disjunction of mitral valve prolapse: presentation and outcome. JACC Cardiovasc Imaging 2021;14:2073-2087. Go to original source... Go to PubMed...
    44. Toh H, Mori S, Izawa Y, Fujita H, Miwa K, Suzuki M, et al. Prevalence and extent of mitral annular disjunction in structurally normal hearts: comprehensive 3D analysis using cardiac computed tomography. Eur Heart J Cardiovasc Imaging 2021;22:614-622. Go to original source... Go to PubMed...
    45. Mantegazza V, Volpato V, Gripari P, Ghulam Ali S, Fusini L, Italiano G, et al. Multimodality imaging assessment of mitral annular disjunction in mitral valve prolapse. Heart 2021;107:25-32. Go to original source... Go to PubMed...
    46. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 2021;384:2081-2091. Go to original source... Go to PubMed...
    47. Bartko PE, Heitzinger G, Pavo N, Heitzinger M, Spinka G, Prausmuller S, et al. Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study. BMJ 2021;373:n1421. Go to original source... Go to PubMed...
    48. Benfari G, Antoine C, Essayagh B, Batista R, Maalouf J, Rossi A, et al. Functional mitral regurgitation outcome and grading in heart failure with reduced ejection fraction. JACC Cardiovasc Imaging 2021;14:2303-2315. Go to original source... Go to PubMed...
    49. Pagnesi M, Adamo M, Sama IE, Anker SD, Cleland JG, Dickstein K, et al. Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. Eur J Heart Fail 2021;23:1750-1758. Go to original source... Go to PubMed...
    50. Michler RE, Smith PK, Parides MK, Ailawadi G, Thourani V, Moskowitz AJ, et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 2016;374:1932-1941. Go to original source... Go to PubMed...
    51. Obadia J-F, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018;379:2297-2306. Go to original source... Go to PubMed...
    52. Mack MJ, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. 3-year outcomes of transcatheter mitral valve repair in patients with heart failure. J Am Coll Cardiol 2021;77:1029-1040. Go to original source... Go to PubMed...
    53. Arnold SV, Stone GW, Jain SS, Mack MJ, Saxon JT, Zhang Z, et al. Prognostic importance of health status versus functional status in heart failure and secondary mitral regurgitation. JACC Heart Fail 2021;9:684-692. Go to original source... Go to PubMed...
    54. Ben-Yehuda O, Shahim B, Chen S, Liu M, Redfors B, Hahn RT, et al. Pulmonary hypertension in transcatheter mitral valve repair for secondary mitral regurgitation: the COAPT trial. J Am Coll Cardiol 2020;76:2595-2606. Go to original source... Go to PubMed...
    55. Giustino G, Lindenfeld J, Abraham WT, Kar S, Lim DS, Grayburn PA, et al. NYHA functional classification and outcomes after transcatheter mitral valve repair in heart failure: the COAPT trial. JACC Cardiovasc Interv 2020;13:2317-2328. Go to original source... Go to PubMed...
    56. Hahn RT, Asch F, Weissman NJ, Grayburn P, Kar S, Lim S, et al. Impact of tricuspid regurgitation on clinical outcomes: the COAPT trial. J Am Coll Cardiol 2020;76:1305-1314. Go to original source... Go to PubMed...
    57. Malik UI, Ambrosy AP, Ku IA, Mishell JM, Kar S, Lim DS, et al. Baseline functional capacity and transcatheter mitral valve repair in heart failure with secondary mitral regurgitation. JACC Cardiovasc Interv 2020;13:2331-2341. Go to original source... Go to PubMed...
    58. Karam N, Stolz L, Orban M, Deseive S, Praz F, Kalbacher D, et al. Impact of right ventricular dysfunction on outcomes after transcatheter edge-to-edge repair for secondary mitral regurgitation. JACC Cardiovasc Imaging 2021;14:768-778. Go to original source... Go to PubMed...
    59. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018;379:2307-2318. Go to original source... Go to PubMed...
    60. Lindenfeld J, Abraham WT, Grayburn PA, Kar S, Asch FM, Lim DS, et al. Association of effective regurgitation orifice area to left ventricular end-diastolic volume ratio with transcatheter mitral valve repair outcomes: a secondary analysis of the COAPT trial. JAMA Cardiol 2021;6:427-436. Go to original source... Go to PubMed...
    61. Iung B, Messika-Zeitoun D, Boutitie F, Trochu JN, Armoiry X, Maucort-Boulch D, et al. Characteristics and outcome of COAPT-eligible patients in the MITRA-FR trial. Circulation 2020;142:2482-2484. Go to original source... Go to PubMed...
    62. Messika-Zeitoun D, Iung B, Armoiry X, Trochu JN, Donal E, Habib G, et al. impact of mitral regurgitation severity and left ventricular remodeling on outcome after Mitraclip implantation: results from the Mitra-FR trial. JACC Cardiovasc Imaging 2021;14:742-752. Go to original source... Go to PubMed...
    63. Kar S, Mack MJ, Lindenfeld J, Abraham WT, Asch FM, Weissman NJ, et al. Relationship between residual mitral regurgitation and clinical and quality-of-life outcomes after transcatheter and medical treatments in heart failure: COAPT trial. Circulation 2021;144:426-437. Go to original source... Go to PubMed...
    64. Bedogni F, Popolo Rubbio A, Grasso C, Adamo M, Denti P, Giordano A, et al. Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and residual mitral regurgitation after MitraClip implantation. Eur J Heart Fail 2021;23:1364-1376. Go to original source... Go to PubMed...
    65. Reichart D, Kalbacher D, Rubsamen N, Tigges E, Thomas C, Schirmer J, et al. The impact of residual mitral regurgitation after MitraClip therapy in functional mitral regurgitation. Eur J Heart Fail 2020;22:1840-1848. Go to original source... Go to PubMed...
    66. Higuchi S, Orban M, Stolz L, Karam N, Praz F, Kalbacher D, et al. Impact of residual mitral regurgitation on survival after transcatheter edge-to-edge repair for secondary mitral regurgitation. JACC Cardiovasc Interv 2021;14:1243-1253. Go to original source... Go to PubMed...
    67. Chikwe J, O'Gara P, Fremes S, Sundt TM 3rd, Habib RH, Gammie J, et al. Mitral surgery after transcatheter edge-to-edge repair: society of thoracic surgeons database analysis. J Am Coll Cardiol 2021;78:1-9. Go to original source... Go to PubMed...
    68. Simonato M, Whisenant B, Ribeiro HB, Webb JG, Kornowski R, Guerrero M, et al. Transcatheter mitral valve replacement after surgical repair or replacement: comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID registry. Circulation 2021;143:104-116. Go to original source... Go to PubMed...
    69. Whisenant B, Kapadia SR, Eleid MF, Kodali SK, McCabe JM, Krishnaswamy A, et al. One-year outcomes of mitral valve-in-valve using the SAPIEN 3 transcatheter heart valve. JAMA Cardiol 2020;5:1245-1252. Go to original source... Go to PubMed...
    70. Freitas-Ferraz AB, Bernier M, Vaillancourt R, Ugalde PA, Nicodème F, Paradis JM, et al. Safety of transesophageal echocardiography to guide structural cardiac interventions. J Am Coll Cardiol 2020;75:3164-3173. Go to original source... Go to PubMed...
    71. Zhan Y, Debs D, Khan MA, Nguyen DT, Graviss EA, Khalaf S, et al. Natural history of functional tricuspid regurgitation quantified by cardiovascular magnetic resonance. J Am Coll Cardiol 2020;76:1291-1301. Go to original source... Go to PubMed...
    72. Dreyfus J, Flagiello M, Bazire B, Eggenspieler F, Viau F, Riant E, et al. Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes. Eur Heart J 2020;41:4304-4317. Go to original source... Go to PubMed...
    73. Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, et al. Concomitant tricuspid repair in patients with degenerative mitral regurgitation. N Engl J Med; {uri{https://doi.org/10.1056/NEJMoa2115961}}. {comment{Published online ahead of print 13 November 2021]}. Go to original source... Go to PubMed...
    74. Montalto C, Sticchi A, Crimi G, Laricchia A, Khokhar A, Giannini F, et al. Functional and echocardiographic improvement after transcatheter repair for tricuspid regurgitation: a systematic review and pooled analysis. JACC Cardiovasc Interv 2020;13:2719-2729. Go to original source... Go to PubMed...
    75. Stocker TJ, Hertell H, Orban M, Braun D, Rommel KP, Ruf T, et al. Cardiopulmonary hemodynamic profile predicts mortality after transcatheter tricuspid valve repair in chronic heart failure. JACC Cardiovasc Interv 2021;14:29-38. Go to original source... Go to PubMed...
    76. Duval X, Le Moing V, Tubiana S, Esposito-Farèse M, Ilic-Habensus E, Leclercq F, et al. Impact of systematic whole-body 18F-fluorodeoxyglucose PET/CT on the management of patients suspected of infective endocarditis: the prospective multicenter TEPvENDO study. Clin Infect Dis 2021;73: 393-403. Go to original source... Go to PubMed...
    77. Barca L V, Vidal-Bonnet L, Farinas MC, Munoz P, Valerio Minero M, de Alarcon A, et al. Analysis of sex differences in the clinical presentation, management and prognosis of infective endocarditis in Spain. Heart 2021;107:1717-1724. Go to original source... Go to PubMed...
    78. Mentias A, Saad M, Desai MY, Krishnaswamy A, Menon V, Horwitz PA, et al. Transcatheter versus surgical aortic valve replacement in patients with rheumatic aortic stenosis. J Am Coll Cardiol 2021;77:1703-1713. Go to original source... Go to PubMed...
    79. Del Val D, Abdel-Wahab M, Mangner N, Durand E, Ihlemann N, Urena M, et al. Stroke complicating infective endocarditis after transcatheter aortic valve replacement. J Am Coll Cardiol 2021;77:2276-2287. Go to original source... Go to PubMed...
    80. McElhinney DB, Zhang Y, Aboulhosn JA, Morray BH, Biernacka EK, Qureshi AM, et al. Multicenter study of endocarditis after transcatheter pulmonary valve replacement. J Am Coll Cardiol 2021;78:575-589. Go to original source... Go to PubMed...
    81. Alkhouli M, Alqahtani F, Simard T, Pislaru S, Schaff HV, Nishimura RA. Predictors of use and outcomes of mechanical valve replacement in the United States (2008-2017). J Am Heart Assoc 2021;10:e019929. Go to original source... Go to PubMed...
    82. awitz OK, Wang TY, Lopes RD, Chavez A, Boyer B, Kim H, et al. Rationale and design of PROACT Xa: a randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. Am Heart J 2020;227:91-99. Go to original source... Go to PubMed...
    83. Zhang B, Salaun E, Côté N, Wu Y, Mahjoub H, Mathieu P, et al. Association of bioprosthetic aortic valve leaflet calcification on hemodynamic and clinical outcomes. J Am Coll Cardiol 2020;76:1737-1748. Go to original source... Go to PubMed...
    84. Kwiecinski J, Tzolos E, Cartlidge TRG, Fletcher A, Doris MK, Bing R, et al. Native aortic valve disease progression and bioprosthetic valve degeneration in patients with transcatheter aortic valve implantation. Circulation 2021;44:1396-1408. Go to original source... Go to PubMed...
    85. Christersson C, James SK, Lindhagen L, Ahlsson A, Friberg O, Jeppsson A, et al. Comparison of warfarin versus antiplatelet therapy after surgical bioprosthetic aortic valve replacement. Heart 2020;106:838-844. Go to original source... Go to PubMed...
    86. Guimaraes HP, Lopes RD, de Barros ESPGM, Liporace IL, Sampaio RO, Tarasoutchi F, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 2020;383:2117-2126. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes